Anteris Technologies Ltd's (ASX:AVR) (OTCMKTS:AMEUF) (FRA:DDF) Wayne Paterson tells Proactive's Andrew Scott its share price has moved up to reflect the progress of the last two years.
''We've delivered on everything we said we'd do in terms of restructuring the company as well as those clinical and pre-clinical results which are critically important''.
Paterson discusses recently received results from an anti-calcification study that indicate its ADAPT® treated tissue has superior anti-calcification attributes compared with tissues used in competitor valves.
''If we really bring out a product that is clinically superior ... then this is the product that will lead the market in the years ahead''.
''We're in good shape .... I feel very confident that the legitimacy of our technology's been proven well beyond doubt at this point and so there's a lot of opportunity for this product to enter what is a huge market''.